These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36032151)

  • 1. Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy.
    Wu L; Wang D; Chen Y; Qian M; Xu X; Zhang T; Bi N; Wang L
    Front Immunol; 2022; 13():906815. PubMed ID: 36032151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
    Mandarano M; Orecchini E; Bellezza G; Vannucci J; Ludovini V; Baglivo S; Tofanetti FR; Chiari R; Loreti E; Puma F; Sidoni A; Belladonna ML
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy.
    Wu L; Gao Y; Wang D; Chen Y; Qian M; Xu X; Zhang T; Bi N; Wang L
    J Oncol; 2023; 2023():3591758. PubMed ID: 36824664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
    Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
    J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between IDO activity and prognosis in patients with non-small cell lung cancer after radiotherapy.
    Zhu Y; Jiang C; Liu Y; Li Y; Wu H; Feng J; Xu Y
    Ann Transl Med; 2020 Sep; 8(18):1169. PubMed ID: 33241018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1.
    Botticelli A; Mezi S; Pomati G; Cerbelli B; Cerbelli E; Roberto M; Giusti R; Cortellini A; Lionetto L; Scagnoli S; Zizzari IG; Nuti M; Simmaco M; Marchetti P
    Front Immunol; 2020; 11():1243. PubMed ID: 32733441
    [No Abstract]   [Full Text] [Related]  

  • 7. Indoleamine 2,3-dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival.
    Souissi S; Ghedira R; Macherki Y; Ben-Haj-Ayed A; Gabbouj S; Remadi Y; Sfar I; Chadli Z; Aouam K; Hassine M; Bouaouina N; Zakhama A; Hassen E
    Immun Inflamm Dis; 2022 Sep; 10(9):e690. PubMed ID: 36039641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
    Wang W; Huang L; Jin JY; Jolly S; Zang Y; Wu H; Yan L; Pi W; Li L; Mellor AL; Kong FS
    Cancer Res; 2018 Feb; 78(3):809-816. PubMed ID: 29118088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced tryptophan-kynurenine metabolism via indoleamine 2,3-dioxygenase 1 induction in dermatomyositis.
    Wu D; Chen M; Chen S; Zhang S; Chen Y; Zhao Q; Xue K; Xue F; Chen X; Zhou M; Li H; Zheng J; Le Y; Cao H
    Clin Rheumatol; 2022 Oct; 41(10):3107-3117. PubMed ID: 35778590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A peripheral blood mononuclear cell-based in vitro model: A tool to explore indoleamine 2, 3-dioxygenase-1 (IDO1).
    Gonçalves M; Furgiuele A; Rasini E; Legnaro M; Ferrari M; Luini A; Rodrigues-Santos P; Caramelo F; Marino F; Pereira FC; Cosentino M
    Eur J Pharmacol; 2024 Apr; 968():176420. PubMed ID: 38367683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer.
    Suzuki Y; Suda T; Furuhashi K; Suzuki M; Fujie M; Hahimoto D; Nakamura Y; Inui N; Nakamura H; Chida K
    Lung Cancer; 2010 Mar; 67(3):361-5. PubMed ID: 19487045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma.
    Meireson A; Ferdinande L; Haspeslagh M; Hennart B; Allorge D; Ost P; Sundahl N; Spaas M; Demeyer A; Brochez L
    Front Immunol; 2021; 12():736498. PubMed ID: 34557196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Validation Study on IDO Immune Biomarkers for Survival Prediction in Non-Small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early-Stage Disease.
    Wang W; Huang L; Jin JY; Pi W; Ellsworth SG; Jolly S; Mellor AL; Machtay M; Kong FS
    Clin Cancer Res; 2020 Jan; 26(1):282-289. PubMed ID: 31471311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.
    Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W
    Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1.
    Liang F; Wang GZ; Wang Y; Yang YN; Wen ZS; Chen DN; Fang WF; Zhang B; Yang L; Zhang C; Han SC; Yang FY; Wang D; Liang LJ; Wang Z; Zhao Y; Wang CL; Zhang L; Zhou GB
    Signal Transduct Target Ther; 2022 Sep; 7(1):311. PubMed ID: 36068203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.
    Creelan BC; Antonia S; Bepler G; Garrett TJ; Simon GR; Soliman HH
    Oncoimmunology; 2013 Mar; 2(3):e23428. PubMed ID: 23802083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer.
    Nguyen DJM; Theodoropoulos G; Li YY; Wu C; Sha W; Feun LG; Lampidis TJ; Savaraj N; Wangpaichitr M
    Mol Cancer Res; 2020 Jan; 18(1):105-117. PubMed ID: 31628200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of IDO1 enzyme activity in normal and malignant tissues.
    Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
    Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
    J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.